Statins as antiarrhythmics: A systematic review part II: Effects on risk of ventricular arrhythmias

Clinical Cardiology

Volumn 32, Issue 10, 2009, Pages 549-552

  Abuissa, Hussam ^a   O'Keefe, James H ^b   Bybee, Kevin A ^b,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PLACEBO; ROSUVASTATIN;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEFIBRILLATOR; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; MORTALITY; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SUDDEN DEATH; SYSTEMATIC REVIEW; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; MULTIMODALITY CANCER THERAPY; RISK FACTOR; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; COMBINED MODALITY THERAPY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 70849132546     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20435     Document Type: Review

References (23)

1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. Oct 3 1996;335(14):1001-1009.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. Jul 6 2002;360(9326):7-22. (Pubitemid 34756487)
3. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. Sep 1 1998;98(9):839-844.
4. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. Feb 1995;15(2):247-251.
5. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. Mar 4 1997;95(5):1126-1131. (Pubitemid 27097821)
6. Di Napoli P, Antonio Taccardi A, Grilli A, Spina R, Felaco M, et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res. Aug 1 2001;51(2):283-293. (Pubitemid 32695539)
7. Bybee KA, Kopecky SL, Williams BA, Murphy JG, Scott Wright R. Reduced creatine kinase release with statin use at the time of myocardial infarction. Int J Cardiol. Sep 2004;96(3):461-466.
8. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, et al. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail. Dec 2005;11(9):684-690. (Pubitemid 41797497)
9. Welzig CM, Shin DG, Park HJ, Kim YJ, Saul JP, et al. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness. Circulation. Dec 2 2003;108(22):2743-2746.
10. De Sutter J, Tavernier R, De Buyzere M, Jordaens L, De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol. Sep 2000;36(3):766-772. (Pubitemid 30681596)
11. Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. Jul 2 2003;42(1):81-87. (Pubitemid 36760765)
12. Chiu JH, Abdelhadi RH, Chung MK, Gurm HS, Marrouche NF, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol. Feb 15 2005; 95(4):490-491. (Pubitemid 40247545)
13. Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. Feb 21 2006;47(4):769-773. (Pubitemid 43243099)
14. Goldberger JJ, Subacius H, Schaechter A, Howard A, Berger R, et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. Sep 19 2006;48(6):1228-1233. (Pubitemid 44363151)
15. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. Nov 29 2007;357(22):2248-2261. (Pubitemid 350190755)
16. Dickinson MG, Ip JH, Olshansky B, Hellkamp AS, Anderson J, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. Apr 2007;153(4):573-578.
17. Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. Feb 28 2006;113(8):1086-1092. (Pubitemid 43754275)
18. Rosolova H, Cech J, Simon J, Spinar J, Jandova R, et al. Short to long term mortality of patients hospitalised with heart failure in the Czech Republic-a report from the EuroHeart Failure Survey. Eur J Heart Fail. Aug 2005;7(5):780-783. (Pubitemid 41125892)
19. Levantesi G, Scarano M, Marfisi R, Borrelli G, Rutjes AW, et al. Meta-analysis of effect of statin treatment on risk of sudden death. Am J Cardiol. Dec 1 2007;100(11):1644-1650. (Pubitemid 350122329)
20. Yamada T, Node K, Mine T, Morita T, Kioka H, et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J. Jun 2007;153(6):1055 e1051-1058. (Pubitemid 46809850)
21. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. Feb 18 2004;43(4):642-648. (Pubitemid 38229538)
22. Budaj A, Cybulski J, Cedro K, Karczmarewicz S, Maciejewicz J, et al. Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction. Randomized, placebo-controlled substudy of ISIS-4. Eur Heart J. Oct 1996;17(10):1506-1510.
23. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. Aug 7 1999;354(9177):447-455.